Tag: ADC
Cohance Lifesciences to merge with Suven Pharmaceuticals
Cohance's ADC Platform addition further strengthens Suven’s position in the high growth CDMO segment; also adds lifecycle management capabilities for Innovators
J&J acquisition of Ambrx bolsters cancer ADC portfolio amidst big pharma’s...
In 2022, the global ADC market for cancer treatment was valued at $7.5 billion, with Roche’s Kadcyla generating $2.2 billion, followed by Daiichi Sankyo’s Enhertu at $1.5 billion
Piramal Pharma Solutions invests $10 million to expand its API ...
The enhanced capability opens the Michigan site up to a new base of customers, including the antibody drug conjugate (ADC) market.............................